SEGRON Announces New Funding Round to Expand Into Industries Building Back From COVID-19 and Accelerating Digital Transformation
7.4.2021 08:00:00 EEST | Business Wire | Press release
SEGRON, a leader in the next generation of active testing, today announces the completion of a new round of funding, bringing total capital raised to-date up to $10million. The funding round, led by OTB Ventures and Credo, comes amid significant momentum for the business, having achieved a leadership position in automation services for the telecoms industry. Proceeds from the raise will be used to fund international growth and expand into new industry verticals that are seeing a resurgence of demand and accelerated digital adoption as a result of the progression of the Covid-19 pandemic.
International scale to capture a $35bn market opportunity
SEGRON offers automated solutions to test new digital services in any location, with any device, anytime. SEGRON’s leadership position in test automation solutions for the telecoms ecosystem enables operators including Telefonica, T-Mobile Group and Swisscom to ensure optimal service quality for end-subscribers while enabling faster go-to-market for next-generation 5G and IoT services.
SEGRON’s success with telecoms operators in the European Union is now attracting attention from a wide array of international players in the global telecoms market. With Covid-19 increasing demand for telecoms services SEGRON has become an attractive partner for telecoms operators facing increased pressures to roll out next-generation networks at pace. This includes expansion into North America with a new agreement with a Canadian telecoms operator. In the year ahead, SEGRON is expecting to expand its global presence further to Middle East and Africa and the Asia-Pacific region.
Expanding from telecoms industry to e-commerce, automotive and consumer electronics
Automated testing also enables businesses undergoing rapid digital transformation to accommodate the growing list of testing requirements to ensure a high-performing user experience. SEGRON’s leadership in the telecoms industry has built momentum to expand into e-commerce, automotive and consumer electronics, with the first major OEM announced in the consumer electronics industry today as global handset manufacturer. The advanced AI based testing automation solution helps to keep pace with the mobile devices evolution, ensuring day 1 availability even with pre-released devices for testing automation.
Today’s new funding enables SEGRON to further expand into these adjacent industries and deploy automated testing solutions to enhance the end user experience while shortening the time-to-market for new products and services. In the next few years, the Company will focus on AI and anticipates the launch of a new product, Global Service Enabler in April 2021 which helps verify the performance of digital services over international and roaming networks from any location.
With the market dynamics in telecoms and new industry verticals, SEGRON anticipates growing by over 300% in the year ahead to achieve annual recurring revenues in excess of $5m on a run-rate basis.
According to Global Market Insights, the automation testing market is expected to grow at 15% CAGR between 2020 and 2026, reaching an estimated global market value of $35bn.
Hiring new talents for accelerated growth
In conjunction with today’s new funding round, SEGRON also announces the appointment of three new executives to the senior management team - Jean-Philippe Leloup joins as Deputy Chief Executive Officer, Rita D’Agostino joins as Chief Marketing Officer and Martin Hochmeister joins as Chief Revenue Officer.
Martin Hochmeister joined with leadership experience in technology business environments, most recently with automation business Scanpoint GMBH where he ran sales and marketing as the business scaled-up its growth within Europe. Rita D’Agostino joined SEGRON with international experience in digital marketing and big data. Rita’s background is in the automotive industry, with a career spanning Fiat Chrysler Automobiles, Kia Corporation and Maserati.
Jean-Philippe Leloup joined SEGRON from IDI Group LLC, an investor in early stage companies playing an active role in business development and value creation. Similar to Rita D’Agostino, Jean-Philippe previously worked in the automotive industry, leading Ferrari's business operations in central and eastern Europe before building Maserati Commercial as a new division within the Italian automaker.
Wireless connectivity in the automotive industry makes SEGRON a highly compelling partner for automotive OEMs looking to adopt technologies ranging from automated robotic assembly lines to self-driving cars. The vast bandwidth and low latency of wireless communication between devices and control systems require continuous and fully automated testing, creating a new market opportunity for SEGRON’s automation solutions.
As SEGRON looks to expand its industrial scale in new industries and international markets, it is anticipated that its workforce will increase by 30% by the end of 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005984/en/
Contact information
Rob Mindell / Valerija Cymbal
FTI Consulting
T: +44 20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
